|
|
|
|
LEADER |
01000naa a22002652 4500 |
001 |
NLM171566238 |
003 |
DE-627 |
005 |
20231223125938.0 |
007 |
tu |
008 |
231223s2007 xx ||||| 00| ||eng c |
028 |
5 |
2 |
|a pubmed24n0572.xml
|
035 |
|
|
|a (DE-627)NLM171566238
|
035 |
|
|
|a (NLM)17640604
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a eng
|
100 |
1 |
|
|a Fu, Yuyang
|e verfasserin
|4 aut
|
245 |
1 |
0 |
|a Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis
|
264 |
|
1 |
|c 2007
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
500 |
|
|
|a Date Completed 18.09.2007
|
500 |
|
|
|a Date Revised 30.03.2022
|
500 |
|
|
|a published: Print
|
500 |
|
|
|a Citation Status MEDLINE
|
520 |
|
|
|a Lupus nephritis is an immune-mediated disease, where antibodies and T cells both play pathogenic roles. Since spontaneous lupus nephritis in mouse models takes 6-12 months to manifest, there is an urgent need for a mouse model that can be used to delineate the pathogenic processes that lead to immune nephritis, over a quicker time frame. We propose that the experimental anti-glomerular basement membrane (GBM) disease model might be a suitable tool for uncovering some of the molecular steps underlying lupus nephritis. This article reviews the current evidence that supports the use of the experimental anti-GBM nephritis model for studying spontaneous lupus nephritis. Importantly, out of about 25 different molecules that have been specifically examined in the experimental anti-GBM model and also spontaneous lupus nephritis, all influence both diseases concordantly, suggesting that the experimental model might be a useful tool for unraveling the molecular basis of spontaneous lupus nephritis. This has important clinical implications, both from the perspective of genetic susceptibility as well as clinical therapeutics
|
650 |
|
4 |
|a Journal Article
|
650 |
|
4 |
|a Review
|
700 |
1 |
|
|a Du, Yong
|e verfasserin
|4 aut
|
700 |
1 |
|
|a Mohan, Chandra
|e verfasserin
|4 aut
|
773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 124(2007), 2 vom: 15. Aug., Seite 109-18
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
773 |
1 |
8 |
|g volume:124
|g year:2007
|g number:2
|g day:15
|g month:08
|g pages:109-18
|
912 |
|
|
|a GBV_USEFLAG_A
|
912 |
|
|
|a SYSFLAG_A
|
912 |
|
|
|a GBV_NLM
|
912 |
|
|
|a GBV_ILN_11
|
912 |
|
|
|a GBV_ILN_24
|
912 |
|
|
|a GBV_ILN_350
|
951 |
|
|
|a AR
|
952 |
|
|
|d 124
|j 2007
|e 2
|b 15
|c 08
|h 109-18
|